JAZZ peer analysis
Jazz Pharmaceuticals (JAZZ) against its competitors: price, today's move, 1-year return and market value side by side.
JAZZ and its peers
| Company | Price | Today | 1-year return | Market cap |
|---|---|---|---|---|
| GMAB Genmab | $54.93 | -3.73% | 91.59% | $35.09B |
| HRMY Harmony Biosciences | $37.90 | -2.22% | 31.14% | – |
| INCY Incyte | $119.99 | -0.33% | 29.59% | $24.54B |
| LEGN Legend Biotech | $21.11 | -2.40% | -34.54% | $4.21B |
| LGND Ligand Pharmaceuticals | $307.23 | -4.81% | 64.24% | $6.43B |
| MGNX MacroGenics | $2.40 | 0.84% | 50.47% | $152.88M |
| NBIX Neurocrine Biosciences | $156.00 | 6.78% | 13.01% | $14.85B |
| TGTX TG Therapeutics | $60.25 | -1.52% | 77.10% | $9.36B |
| JAZZ Jazz Pharmaceuticals | $214.43 | -0.72% | 57.32% | $14.02B |
- JAZZ's peers: GMAB (Genmab), HRMY (Harmony Biosciences), INCY (Incyte), LEGN (Legend Biotech), LGND (Ligand Pharmaceuticals), MGNX (MacroGenics), NBIX (Neurocrine Biosciences), TGTX (TG Therapeutics).
Updated 2026-11-03 01:05 UTC